TICKERNERD
Menu
ALVOALVOHealthcare · Drug Manufacturers - Specialty & Generic

ALVO Stock Forecast: Alvotech Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.42
+3.51% on the day

The 6 Wall Street analysts covering Alvotech hold a median 12-month price target of $5 — +13.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.5B
Ticker Nerd rank
26 / 100
Median analyst target
$5.00
Analysts covering
6
Total return, dividends reinvested
1W
+9.0%
1M
+25.6%
YTD
−13.8%
1Y
−47.8%
From 52W high
−50.8%
From 52W low
+47.3%
$3.00
$8.98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alvotech on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
95
Value
88
Volatility
78
Size
38
Revisions
35
Growth
24
Accruals
21
Issuance
11
Momentum
7

Quality (95): The business earns solid, repeatable profits on what it owns.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00$9.00Oct 25Jan 26Apr 26Jul 26ALVOHigh $9.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
4 Buy1 Hold1 Sell
Low $4.00Median $5.00High $9.00

The green dot is the last close — the median target sits +13.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026Evercore ISI GroupInitiatesOutperform—
24 Mar 2026BarclaysMaintainsUnderweight$5.00 → $4.00
24 Mar 2026BarclaysMaintainsUnderweight—
24 Mar 2026UBSMaintainsBuy$10 → $6.00
24 Mar 2026UBSMaintainsBuy—
9 Dec 2025BarclaysInitiatesUnderweight—
18 Nov 2025UBSMaintainsBuy—
4 Nov 2025Deutsche BankDowngradeHold—
14 Oct 2025Morgan StanleyUpgradeOverweight—
23 Sept 2025Deutsche BankUpgradeBuy—
18 July 2025UBSMaintainsBuy—
14 Feb 2025UBSInitiatesBuy—
25 July 2024BarclaysMaintainsOverweight—
24 May 2024BarclaysMaintainsOverweight—
22 Mar 2024BarclaysMaintainsOverweight—
29 Jan 2024BarclaysUpgradeOverweight—
20 Oct 2023CitigroupUpgradeNeutral—
21 Sept 2023BarclaysInitiatesEqual-Weight—
7 Mar 2023Deutsche BankMaintainsHold—
7 Sept 2022Morgan StanleyInitiatesEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALVO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ALVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−62.5%
Analysts raising
0
Analysts cutting
2
Fundamentals

Alvotech (ALVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
42.4×

Cheaper than 18% of US stocks

Price / sales
3.0×

Cheaper than 42% of US stocks

Price / book
−4.9×

Cheaper than 97% of US stocks

EV / EBITDA
38.2×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
−38.9%

Higher than 7% of US stocks

Earnings growth (YoY)
−20.3%

Higher than 20% of US stocks

Gross margin
56.5%

Higher than 69% of US stocks

Operating margin
−11.1%

Higher than 24% of US stocks

Net margin
−36.3%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−9.8%

Higher than 36% of US stocks

Return on assets
2.2%

Higher than 60% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ALVOAlvotech$1.5B
26
ANIPANI Pharmaceuticals, Inc.$1.7B
95
ETONEton Pharmaceuticals, Inc.$1.8B
99
PRGOPerrigo Co. Plc$2.0B
69
HROWHarrow, Inc.$1.5B
49
PAHCPhibro Animal Health Corp.$1.5B
89
TRLVTrulieve Cannabis Corp.$2.1B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alvotech — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALVO news & analysis

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

GlobeNewsWire · 21 Aug 2026positive

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two of its biosimilar candidates—AVT34 (proposed biosimilar to durvalumab) and AVT87 (proposed biosimilar to emicizumab)—for the United States and selected Asian markets.

Why it matters — The agreement expands the commercial reach of Alvotech's pipeline candidates into the U.S. and Asian markets through a partnership with Lotus Pharmaceutical.

Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts

Seeking Alpha · 20 Aug 2026neutral

Alvotech maintains a Hold rating amid missed H1 2026 earnings and regulatory challenges, despite pipeline progress. FDA CRLs for AVT05 and AVT06 were attributed to manufacturing issues that have been addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026, while AVT06 has global commercialization rights secured post-November 2026.

Why it matters — Alvotech watchers would care because the resubmitted BLAs for AVT05 and AVT06, with approvals targeted for Q4 2026 and AVT06's secured global commercialization rights, represent key upcoming catalysts for the company's pipeline.

Alvotech (ALVO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 20 Aug 2026neutral

Seeking Alpha published the transcript of Alvotech's (ALVO) Q2 2026 earnings call. The excerpt confirms the transcript of the company's second-quarter 2026 earnings call is now available.

Why it matters — The transcript provides ALVO watchers with a record of management's discussion of the company's second-quarter 2026 results and outlook.

Alvotech Q2 Earnings Call Highlights

MarketBeat · 20 Aug 2026neutral

Alvotech reported first-half 2026 results reflecting a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site. Management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and product launches.

Why it matters — ALVO watchers would care because the company maintained its full-year guidance despite the temporary slowdown, with upcoming regulatory decisions and launches potentially shaping its outlook.

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 19 Aug 2026negative

Alvotech reported a second-quarter loss of $0.11 per share, wider than the Zacks Consensus Estimate of a $0.06 per share loss and a reversal from earnings of $0.14 per share a year earlier. The company beat revenue expectations for the quarter.

Why it matters — Alvotech watchers would care because the quarterly loss came in wider than analysts forecast and marked a sharp downturn from profitability a year ago, despite a revenue beat.

FAQ

Frequently asked questions about ALVO stock

What is the ALVO stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Alvotech have a median 12-month price target of $5, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALVO stock a buy right now?

Of the 6 analysts covering Alvotech, 4 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alvotech 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALVO?

As at 22 Aug 2026, Alvotech ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (95 of 100).

Will ALVO stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +13.1% from the last close, and Ticker Nerd's factor model ranks Alvotech 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALVO stock forecast for 2030?

No analyst covering Alvotech publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has ALVO stock performed over the past year?

Alvotech returned -47.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alvotech do?

Alvotech S.A. is a global biopharmaceutical company specializing in the development, manufacturing, and delivery of high-quality biosimilar medicines.

What is the latest news on ALVO?

The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets". Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two of its biosimilar candidates—AVT34 (proposed biosimilar to durvalumab) and AVT87 (proposed biosimilar to emicizumab)—for the United States and selected Asian markets.

Company

About Alvotech.

Alvotech S.A. is a global biopharmaceutical company specializing in the development, manufacturing, and delivery of high-quality biosimilar medicines. Biosimilars are biologic products highly similar to approved reference medicines, designed to expand patient access to affordable treatments for conditions in areas such as oncology, immunology, and autoimmune diseases. The company employs a vertically integrated approach, managing processes from cell line development through fill-and-finish manufacturing, which enables control over quality, scale, and efficiency. Alvotech maintains a robust pipeline of biosimilar candidates targeting major therapeutic needs and relies on strategic partnerships with pharmaceutical companies for global commercialization. This model supports its mission to make proven biologic therapies accessible to patients worldwide. Founded in 2013 and headquartered in Reykjavik, Iceland, Alvotech focuses on producing cost-competitive alternatives that meet rigorous standards while enhancing healthcare outcomes through expanded availability of essential medicines.

CEO Mr. Robert Wessman · 1,279 employees · Luxembourg · https://www.alvotech.com